CHICAGO (Reuters) - People with mild heart failure lived longer and fared better by adding Pfizer’s drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday.
CHICAGO (Reuters) - People with mild heart failure lived longer and fared better by adding Pfizer’s drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday.
